CMPS · Q3 2025 results

COMPASS Pathways plc Q3 2025 Earnings Recap

Published November 5, 2025

COMPASS Pathways reported significant progress in its Phase III trials for COMP360, with an accelerated NDA filing timeline now targeted for Q1 2026, positioning the company for potential market entry into treatment-resistant depression (TRD).

The numbers

Reported results against what analysts expected.

Earnings per share $-1.44 vs $-0.40 expected · missed by 260.0%
Nov 5 to Nov 11 -4.4% the days after
Nov 5 to Dec 1 -12.72% the weeks after

Key takeaways

From the Q3 2025 earnings call.

  • The completion of enrollment in the COMP006 trial enhances clarity for data readouts and regulatory timelines.
  • Positive discussions with the FDA support a rolling NDA submission strategy and a potential accelerated launch.
  • Cash reserves stand at $186 million, providing a runway into 2027, with disciplined spending amid ongoing operational expenditures.
  • Ongoing preparations for commercial launch leverage insights from provider dynamics and patient preferences, aiming for effective integration into expanding psychiatric treatment infrastructure.
Your portfolio

Track earnings for the stocks you own

Add your portfolio once, by connecting your broker or importing your history. When a company you hold reports, you get a recap like this one by email, with how the stock moved.

Also published on November 5, 2025

This summary was written by AI from the official earnings call transcript. It is for information only and is not financial advice. For CMPS's price history and fundamentals, see the CMPS stock page.